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Aims The population with stable coronary artery disease (SCAD) is growing but validated models to guide their clinical man-
agement are lacking. We developed and validated prognostic models for all-cause mortality and non-fatal myocardial in-
farction (MI) or coronary death in SCAD.
Methods
and results
Models were developed in a linked electronic health records cohort of 102 023 SCAD patients from the CALIBER pro-
gramme, with mean follow-up of 4.4 (SD 2.8) years during which 20 817 deaths and 8856 coronary outcomes were
observed. The Kaplan–Meier 5-year risk was 20.6% (95% CI, 20.3, 20.9) for mortality and 9.7% (95% CI, 9.4, 9.9) for
non-fatal MI or coronary death. The predictors in the models were age, sex, CAD diagnosis, deprivation, smoking, hyper-
tension, diabetes, lipids, heart failure, peripheral arterial disease, atrial fibrillation, stroke, chronic kidney disease, chronic
pulmonary disease, liver disease, cancer, depression, anxiety, heart rate, creatinine, white cell count, and haemoglobin.
The models had good calibration and discrimination in internal (external) validation with C-index 0.811 (0.735) for
all-cause mortality and 0.778 (0.718) for non-fatal MI or coronary death. Using these models to identify patients at
high risk (defined by guidelines as 3% annual mortality) and support a management decision associated with hazard
ratio 0.8 could save an additional 13–16 life years or 15–18 coronary event-free years per 1000 patients screened, com-
pared with models with just age, sex, and deprivation.
Conclusion These validated prognostic models could be used in clinical practice to support risk stratification as recommended in
clinical guidelines.
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Introduction
Population ageing and improvements in survival after acute coronary
syndromes (ACS) have contributed to worldwide increases in the
number of patients with stable coronary artery disease (SCAD).
Stable coronary artery disease encompasses a heterogeneous spec-
trum of syndromes including patients with stable angina and those
who have become stable after ACS.1,2 In the USA alone, over 16
million people (7% of the US population) suffer from coronary
disease with 500 000 new stable angina cases being reported each
year.3 The 2012 ACCF/AHA guidelines for prognostication in
SCAD recommend that patients are stratified into high (.3%), inter-
mediate (1–3%), and low (,1%) annual mortality risk groups, which
then define different investigation and treatment pathways.4
So far, prognostic models proposed for SCAD (compared in Sup-
plementary material online, Table S1) have been based on data
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collected for research purposes rather than the information that clini-
cians record in real-world practice, and none has been recommended
for clinical use.4–6 Among their limitations is the failure to incorporate
the ‘broad range of relevant data’ identified as important in the guide-
lines, such as sociodemographic characteristics, cardiovascular (CVD)
and non-CVD comorbidities, mental health, symptom severity, and
clinically available biomarkers.4 These data are routinely recorded for
most patients before more costly information becomes available
fromfurther,often invasive, investigations.Other limitationsofprevious
models include the use of selected samples from trials7,8 or voluntary
registries,9 and covering a narrow range of SCAD such as excluding9
or being confined to post-ACS patients.7 Furthermore, the ACCF/
AHA guidelines emphasize the importance of both all-cause mortality
and coronary events as outcomes, but no previous studies have
assessed both. Importantly, none of the previous models has been
validated in an external data set.
We sought to address these limitations by analysing large-scale,
population-based, linked electronic health records data. Our object-
ive was to develop and validate the performance of prognostic
models that incorporate clinical measures recommended in guide-
lines and are commonly available in patients with SCAD.10 Following
recent methodological guidance,11,12 we assessed the accuracyof the
predictions from the prognostic models based on their calibration,
discrimination (C-index), and reclassification improvement.13 To
further evaluate potential clinical benefits, we estimated life years
saved when the models are used to guide management decisions.14
Based on these analyses, we developed prognostic models to
predict all-cause mortality and non-fatal myocardial infarction (MI)
or coronary death in SCAD and evaluated their performance in an in-
dependent data set.
Methods
Patient population
We report findings from the CALIBER (CArdiovascular disease research
using Linked BEspoke studies and Electronic Health Records) collabor-
ation where we linked population-based primary care data from the
Clinical Practice Research Datalink (CPRD) to three further sources of
electronic health records: the Myocardial Ischaemia National Audit
Project registry (MINAP), discharge records from Hospital Episodes Sta-
tistics (HES), and cause-specific mortality from the Office for National
Statistics (ONS), as previously described.15 Eligible patients were those
with a diagnosis of stable angina, patients with history of MI, coronary
artery bypass graft (CABG), or percutaneous coronary intervention
(PCI) prior to the start of the study period (other CHD) and patients
with a diagnosis of ACS within the study period (unstable angina or
acute MI). Myocardial infarction was classified into ST-elevation MI
(STEMI) and non-ST-elevation MI (NSTEMI) where MI type was
recorded (Figure 1). Diagnoses were identified in CPRD, HES, or
MINAP records according to definitions in the CALIBER data manual.15
Stable angina was defined by Read codes in CPRD for angina diagnosis,
positive ischaemia tests, coronary angiogram results recorded or
repeat prescriptions for nitrates, or hospitalizations with a primary
spell diagnosis ICD10 code I20.1, I20.8, or I20.9. Unstable angina was
defined by Read codes in CPRD or hospital admission with ICD10
code I20.0. ST-elevation MI and NSTEMI were defined according to
the discharge diagnosis as recorded in MINAP. Acute MI not otherwise
specified was defined by Read codes in CPRD or ICD10 I21–I22 as the
primary diagnosis in HES. Furtherdetails on thediagnostic codes and defi-
nitions used are available at http://www.caliberresearch.org/portal/.
Patients with prior ACS were defined as stable if they had survived
more than 6 months following the acute event, entering the cohort at
this point. We chose 6 months (i) to differentiate long-term prognosis
fromthehigh-riskperiod that typically followsACS or revascularization16
and (ii) because models validated for clinical use following ACS cover the
first 6 months post-ACS (e.g. GRACE17).
Prognostic factors
Candidate predictors were drawn based on recommendations in recent
guidelines for the management of SCAD.4,5 We included demographic
measures (age, sex, ethnicity, social deprivation), SCAD subtype
(stable angina, other CHD, unstable angina, MI, STEMI, NSTEMI), use
of short- and long-acting nitrates, whether CABG or PCI was performed
in the 6 months following CAD diagnosis, previous MI, smoking, body
mass index (BMI), blood pressure, diagnosis of hypertension, diabetes,
lipids, family history of coronary heart disease, CVD comorbidities
[heart failure, peripheral arterial disease (PAD), atrial fibrillation,
stroke], non-CVD comorbidities (chronic renal disease, chronic
Figure 1 Study flow diagram.
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obstructive pulmonary disease, thyroid disorders, peptic ulcer, rheuma-
toid arthritis, cancer, chronic liver disease), psychosocial characteristics
(depression, anxiety), and clinically assessed biomarkers (heart rate,
white cell count, haemoglobin, creatinine, liver enzymes, HbA1c). We
defined as baseline the most recent measurements encompassing
those made up to 6 months prior to cohort entry.
Endpoints
The endpoints were all-cause mortality and a composite of non-fatal MI
or coronary death. Patients were censored at the earliest date among
date of endpoint of interest, relocation to a new primary care practice,
or study end date (25 March 2010).
Model development
Prognostic models were developed and evaluated following the checklist
outlined in the Transparent Reporting of a model for Individual Prognosis
Or Diagnosis (TRIPOD) guidelines.18 The baseline hazard for both out-
comes followed an exponential distribution; hence, we developed expo-
nential proportional hazards models. These are similar to the Cox model
in that they assume proportional hazards but the baseline hazard is para-
metrically estimated based on the exponential model. Log of hazard vs.
log of time plots showed no significant violations of the proportional
hazards assumption. Nonlinear associations were modelled using
splines. Multiple imputation was used to replace missing values in prog-
nostic factors that appeared to have a missing-at-random pattern
(details in Supplementary material online). All candidate models a priori
included age, sex, SCAD subtype, use of long-acting nitrates, CABG/
PCI in the last 6 months, previous/recurrent MI, and CVD risk factors
(smoking, hypertension, diabetes, total, and HDL cholesterol). Addition-
al predictors were selected based on their recording coverage and multi-
variate effect size. Because our data set is large, to decide which variables
to include in the models we defined as ‘moderately significant’ those with
P-values,0.001, and ‘highly significant’ thosewithP-values,1025.Thus,
we examined the multiply imputed multivariate associations of candidate
predictors, adjusted for all other candidate variables (see Supplementary
material online, Tables S4 and S5). Predictors with nonlinear associations
(e.g. BMI) were modelled using restricted cubic splines (three knot points
were sufficient). Predictors with moderate significance after imputation
in the multivariate context were retained in the models if the missing
data did not exceed 50%. Predictors with high significance after imput-
ation were included if their coverage was at least 20%. Subsequently,
weexamined interactionsbetween age and sexwitheachof themodelled
predictors. For simplicity, only the age–sex interaction which was highly
significant was included in the final models.
Evaluation of prediction performance
Discrimination was assessed based on Harrell’s C-index.19 The contribu-
tion of individual prognostic factors to the C-index of the full model was
assessed by backward elimination of a different variable at each iteration.
The ACCF/AHA guidelines classify low- and high-risk patients as those
with ,1 and .3% annual mortality, respectively.4 We extended these
cut-offs to a 5-year time horizon (low ,5%, intermediate 5–14%, high
.15%) to assess the net reclassification improvement (NRI)13 upon add-
ition of different prognostic factors to the models. Calibration of 5-year
risk predictions was visually assessed by comparing predicted vs.
observed (Kaplan–Meier) risk by splitting the data into 10 subgroups
with equal numbers of patients.
Estimation of life years saved
We compared the likely clinical impact of using our prognostic models to
guide medical decisions by estimating the incremental number of life years
saved by using these models over alternative models, as previously
described.14 Briefly, suppose that among a cohort of size N a prognostic
model identified n patients as high risk. Suppose that upon follow-up the
observed survival in these patients was S(t). If a risk management decision
associated with benefit (hazard ratio) u was applied to high-risk patients,
the anticipated risk reduction over time t would be S(t)u–S(t). Estimation
of the number of life years saved by using the prognostic model takes
into account the number of patients identified as high risk by the model
and the expected benefit and cost (medical or other) incurred over time
t if specific management decisions were applied to high-risk patients. For
the current analysis, we defined as high-risk patients those with ≥15%
5-year risk (20% in sensitivity analysis). We assumed that the management
decision (e.g. further testingor treatments) is associatedwithahazard ratio
of 0.8 (20% risk reduction) [for context, antiplatelet therapy has been
shown to reduce risk of fatal/non-fatal CVD by 20% in patients with
prior MI or confirmed CAD20]. Further, we assumed that the cost asso-
ciated with implementing the decision balances the benefit obtained in
patients with 15% 5-year risk (i.e. treating people with higher or lower
observed risk results in positive or negative net benefit, respectively).
Validation
We validated models internally (in CALIBER) and externally (different
study and clinical setting).21 Within CALIBER, we estimated bootstrap
standard errors (200 samples) to obtain optimism-corrected confidence
intervals.22 For external validation, the models developed in CALIBER
were applied to 4020 patients in the ‘Appropriateness of Coronary
Revascularisation’ (ACRE) study, a prospective cohort of patients, with
similar case-mix to patients in our data, who underwent coronaryangiog-
raphy at the London Chest Hospital during 1996/1997 and followed up
until 2004. Details of this study have been previously described.23 Covari-
ates in ACRE that were incompletely recorded (smoking, TCHOL, HDL,
heart rate, blood pressure, creatinine, haemoglobin, white cell count)
were multiply imputed as described for the development data set, but in-
dependently of the CALIBER data. The following candidate predictors
considered in our model development had not been collected by the
ACRE investigators: history of anxiety, depression, cancer, liver disease,
and atrial fibrillation (all binary). To allow models containing these vari-
ables to be evaluated in ACRE, we set these to 0. Discrimination and cali-
bration statistics for 5-year risks predictions in the external data set were
assessed as in the main analysis.
All analyses were performed in the R statistical package, version 2.15.2
for Unix.
Results
Baseline patient characteristics in different
forms of stable coronary artery disease
We included 102 023 patients, of whom 44.7% had stable angina,
21.5% other CHD, 13.0% unstable angina, 4.7% STEMI, 6.7%
NSTEMI, and 9.4% had unclassified MI as their qualifying diagnosis.
Compared with other patients with SCAD, STEMI patients were
younger, more likely to be male and smokers, more likely to
receive PCI, had fewer comorbidities and lower SBP and heart rate
(Supplementary material online, Table S2).
Five-year risks of all-cause mortality and
non-fatal MI or coronary death
The Kaplan–Meier 5-year mortality risk was 20.6% (95% CI, 20.3,
20.9%) but differed markedly among different SCAD subtypes
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(Figure 2). The lowest 5-year mortality was observed in stable angina
patients and those stable afterSTEMI and thehighest in stable patients
after NSTEMI. The observed 5-year risk of non-fatal MI or coronary
death was approximately half that of all-cause mortality [9.7% (95%
CI, 9.4, 9.9%)], but more heterogeneous among SCAD subtypes,
with the lowest seen in patients with stable angina and the highest
in stable patients after NSTEMI.
Prognostic factors
The age- and sex-adjusted associations of candidate prognostic
factors with either of the two endpoints were comparable among
the different SCAD subtypes (Supplementary material online,
Tables S3 and S4). Male sex was associated with higher risks in all
forms of SCAD except after MI, whereas age was a stronger risk
factor in women. Body mass index had a U shape association with all-
cause mortality and a positive linear association with coronary out-
comes, in both cases changing to L shape after multiple adjustments
(Supplementary material online, Table S5). Because of the potential
for over-adjustment when diabetes, hypertension, and other factors
strongly associated with obesity were included,24 BMI was not
included in the final models. Hyperthyroidism and high HbA1c had
significant univariate but weak multivariate associations. All continu-
ous predictors appearing in the final models were approximately lin-
early associated with the corresponding outcomes.
The CALIBERmodels
We developedmodels forall-cause mortality andnon-fatal MIorcor-
onary death that include the following prognostic factors (different
coefficients for each endpoint);age, sex, deprivation, SCAD
subtype, recent revascularizations, previous MI, use of long-acting
nitrates, diabetes, hypertension, smoking, lipids, heart failure, PAD,
atrial fibrillation, stroke, chronic renal disease, chronic obstructive
pulmonary disease, cancer, chronic liver disease, depression,
anxiety, heart rate, creatinine, white cell count, and haemoglobin
(Table 1).
Discrimination and calibration
In internal validation, theC-indexwas0.811 (95%CI, 0.806, 0.816) for
all-cause mortality and 0.778 (95% CI, 0.770, 0.785) for non-fatal MI
or coronary death. For interpretation, a model with C-index 0.811
correctly predicts who will have an event earlier between two
patients 81.1% of the times, a significant improvement over a
random 50% guess. The models were well calibrated throughout
the risk range (Supplementary material online, Figure S1).
Contribution of prognostic factors to
model performance
Predictors based on initial CAD diagnosis, CVD co-morbidities, and
biomarkers contributed the largest increments in the C-index
(Figure 3). For prediction of all-cause mortality, the predictors with
the largest influence on the discrimination of the model were (in
order of decreasing contribution to the C-index): creatinine, total
and HDL cholesterol, SCAD subtype with revascularization status,
depression, heart rate, and chronic obstructive pulmonary disease.
Equivalently for prediction of MI and coronary death, the most influ-
ential predictors were SCAD subtype, haemoglobin, heart failure,
use of nitrates, diabetes, PAD, white cell count, and previous MI.
Other non-CVD comorbidities contributed to the prediction of all-
cause mortality only, whereas diagnosis of hypertension did not lead
to gain in discrimination performance for either endpoint.
Evaluation of potential clinical impact
To evaluate the potential clinical impact of using these models for
clinical evaluation of patients with SCAD, the full models were com-
pared with one with just demographic characteristics (Figure 4 and
Supplementary material online, Figure S1). Based on 5-year risk pre-
dictions, the NRI was 0.35 (95% CI, 0.34, 0.36) for all-cause mortality
and 0.24 (95% CI, 0.23, 0.26) for non-fatal MI or coronary death. For
interpretation, an NRI of 0.35 in the current context means that in a
population of patients classified into three categories according to
their 5-year risk predictions (,5, 5–14, and .15%) based on an
Figure 2 Observed (Kaplan–Meier) risk of all cause-mortality and non-fatal MI or coronary death for stable angina patients and stable patients 6
months after ACS. The numbers of patients at risk per unit time are shown below each plot.
Prognostic models for SCAD based on electronic health record cohort 847
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 TheCALIBERmodels for prognosis of all-causemortality and non-fatalmyocardial infarction or coronary death
in stable coronary artery disease
Prognostic factors All-cause mortality,
HRa (95% CI)
Non-fatal MI or coronary death,
HRb (95% CI)
Sociodemographic characteristics
Age in men, per year 1.065 (1.063–1.067) 1.046 (1.043–1.048)
Age in women, per year 1.081 (1.078–1.083) 1.065 (1.061–1.069)
Women vs. men 0.204 (0.162–0.257) 0.158 (0.112–0.221)
Most deprived quintile, yes vs. no 1.151 (1.111–1.192) 1.117 (1.060–1.178)
SCAD diagnosis and severity
Other CHD vs. stable angina 1.024 (0.982–1.067) 1.180 (1.107–1.257)
Unstable angina vs. stable angina 1.021 (0.970–1.075) 1.323 (1.232–1.421)
NSTEMI vs. stable angina 1.298 (1.238–1.360) 2.373 (2.217–2.539)
STEMI vs. stable angina 1.083 (1.006–1.166) 1.940 (1.750–2.149)
PCI in last 6 months, yes vs. no 0.651 (0.605–0.699) 0.702 (0.642–0.768)
CABG in last 6 months, yes vs. no 0.516 (0.469–0.566) 0.424 (0.370–0.486)
Previous/recurrent MI, yes vs. no 1.136 (1.095–1.179) 1.399 (1.330–1.472)
Use of nitrates, yes vs. no 1.152 (1.118–1.188) 1.405 (1.342–1.470)
CVD risk factors
Ex-smoker vs. never 1.110 (1.065–1.157) 1.094 (1.008–1.188)
Current smoker vs. never 1.315 (1.245–1.389) 1.215 (1.126–1.311)
Hypertension, present vs. absent 0.965 (0.929–1.001) 1.064 (1.000–1.131)
Diabetes mellitus, present vs. absent 1.203 (1.160–1.248) 1.387 (1.315–1.463)
Total cholesterol, per 1 mmol/L increase 1.012 (0.983–1.042) 1.061 (1.029–1.094)
HDL, per 0.5 mmol/L increase 1.006 (0.987–1.025) 0.910 (0.879–0.942)
CVD co-morbidities
Heart failure, present vs. absent 1.543 (1.495–1.593) 1.181 (1.089–1.281)
Peripheral arterial disease, present vs. absent 1.286 (1.234–1.340) 1.085 (1.031–1.142)
Atrial fibrillation, present vs. absent 1.280 (1.236–1.326) 0.952 (0.887–1.021)
Stroke, present vs. absent 1.329 (1.277–1.382) 1.138 (0.925–1.401)
Non-CVD comorbidities
Chronic kidney disease, present vs. absent 1.116 (1.058–1.178) 1.085 (1.031–1.142)
Chronic obstructive pulmonary disease, present vs. absent 1.150 (1.114–1.187) 1.181 (1.089–1.281)
Cancer, present vs. absent 1.377 (1.324–1.432) 0.952 (0.887–1.021)
Chronic liver disease, present vs. absent 1.631 (1.443–1.842) 1.138 (0.925–1.401)
Psychosocial characteristics
Depression at diagnosis, present vs. absent 1.179 (1.135–1.225) 1.059 (0.998–1.124)
Anxiety at diagnosis, present vs. absent 1.172 (1.116–1.231) 1.015 (0.937–1.100)
Biomarkers
Heart rate, per 10 b.p.m increase 1.098 (1.084–1.112) 1.069 (1.030–1.110)
Creatinine, per 30 mmol/L increase 1.065 (1.051–1.080) 1.087 (1.064–1.110)
White cell count, per 1.5 109/L increase 1.120 (1.106–1.135) 1.111 (1.088–1.135)
Haemoglobin, per 1.5 g/dL increase 0.758 (0.724–0.794) 0.822 (0.800–0.845)
C-index
Internal cross-validation 0.811 (0.806–0.816) 0.778 (0.770–0.785)
External validation (ACRE) 0.735 (0.715–0.755) 0.718 (0.700–0.736)
CABG, coronary artery bypass graft; SCAD, stable coronary artery disease; HDL, high-density lipoprotein cholesterol; MI, myocardial infarction; NSTEMI, non-ST-segment elevation
MI; PAD peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation MI.
aExponential proportional hazards regression with scale 92 (95% CI, 89, 94).
bExponential proportional hazards regression with scale 88 (95% CI, 84, 92).
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existing model, updating the model by including further risk factors
correctly reclassifies 35% of the patients into risk groups that are
more concordant with their observed event rates, i.e. patients are
moved to the lower risk category if their observed event rate was
low and vice versa. If specific management strategies were recom-
mended for high-risk patients (.15% 5-year risk), and implementa-
tion of these management strategies was associated with hazard
ratio 0.8, using the CALIBER models to estimate 5-year risk would
save an additional 14.5 (95% CI, 13.0, 16.0) life years or 16.1 (95%
CI, 14.6, 17.6) non-fatal MI or coronary death-free years for every
1000 patients screened. Using a 20% threshold to define high-risk
patients led to similar conclusions.
External validation
For external validation, we applied the CALIBER models to patients
in the ACRE study, summarized in Supplementary material online,
Table S6. During a median follow-up of 7.5 years, 872 deaths and
1238 non-fatal MI or coronary deaths were observed among 4020
patients. The C-index was 0.735 (95% CI, 0.715, 0.755) for all-cause
mortality and 0.718 (95% CI, 0.700, 0.736) for non-fatal MI or coron-
ary death. Five-year risks were well calibrated (Supplementary
material online, Figure S1). In sensitivity analysis, we built and evalu-
ated models in CALIBER that omitted the predictors missing in
ACRE (history of depression, anxiety, caner, liver disease, and
atrial fibrillation); the corresponding performance was very similar
to that observed for the full models (where missing predictors
were set to 0).
Risk calculation example
The models proposed are available online at www.caliberresearch.
org/model. Scoring tables25 to simplify the estimation of the risk
scores offline are provided in Supplementary material online.
Suppose we wish to assess the prognosis of a 65-year old man,
who recently survived a STEMI and has remained stable for the last
6 months. He is a current smoker, suffers from diabetes, and has fre-
quent bouts of angina, which he controls using nitrates. He has no
other history of CVD but suffers with depression and chronic ob-
structive pulmonary disease. His pulse rate is 80 b.p.m. and his
current blood measurements are: total cholesterol 7 mmol/L, HDL
cholesterol 2 mmol/L, creatinine 100 mmol/L, white blood count
10 × 109/L, and haemoglobin 14 g/L. No revascularization proced-
ure was performed following his heart attack. From the scoring
tables provided, we have total score for death model ¼ 146 , corre-
sponding to12.5%5-year riskofdeath; total score forMI/fatalCHD
model ¼ 202, corresponding to 6% 5-year risk of MI/coronary
death. According to the guidelines, patients with annual risk of
death or MI.3% (.15% risk over 5 years) are candidates for revas-
cularization. This patient’s mortality risk is near this threshold, so he
should be assessed further (e.g. ECG, angiography) to confirm his
suitability for revascularization.
Discussion
In a population-based study of.100 000 stable patients with a range
of previous CAD phenotypes, we found that prognostic models
Figure3 The contribution of each variable included in the CALIBER model for predicting all-cause mortality in SCAD, assessed by the decrease in
the C-index upon its removal from the complete model.
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combining a wide range of clinical data commonly available prior to
the decision for further investigation can identify patients at high
risk of long-term mortality and coronary events. We demonstrate
how real-world clinical data (as distinct from research data7,8) con-
tribute important prognostic information in unselected patients.
Unlike previous reports of prognostic models,1,7– 9 we focus on
potential clinical usefulness and demonstrate how each predictor
usefully improves predictions beyond more simple models. Import-
antly, we confirm that the models have good calibration and discrim-
ination when applied to an external study.These validated prognostic
models could be used clinically to support risk assessment according
to clinical variables, which is ‘essential for determining optimal treat-
ment strategies’.4
Current practice guidelines informed several aspects of this ana-
lysis.4,5 Because risks in SCAD are heterogeneous and many patients
have low risk, the 2012 ACCF/AHA4 and 2006 ESC5 guidelines
proposea stepwise risk assessment to inform managementdecisions.
The assessment should start with evaluating all patients based on
simple clinical parameters, followed by advanced investigations
(imaging and stress testing) in selected patients, followed by angiog-
raphy conditional on results from earlier steps. The CALIBER
prognostic models incorporate the broad range of clinical character-
istics highlighted by these guidelines for the initial evaluation step,
manyofwhich (deprivation, atrial fibrillation, cancer, liverdisease, de-
pression, anxiety, and haemoglobin) have not previously been incor-
porated in prognostic models for SCAD. Importantly, to make the
evaluation of the models relevant to the guidelines, we used the
ACCF/AHA definition of low, intermediate, and high risk to estimate
the NRI and life years gained from applying these models. Hence, our
evaluation outcomes are clinically relevant.
We present both all-cause mortality and non-fatal MI or coronary
death as outcomes because these risks differ and the best course of
action in terms of risk management and priorities requires evaluation
of both mortality and coronary morbidity. Some prognostic factors
included in the CALIBER models were much more useful for predict-
ing all-cause mortality than coronary risks and vice versa. Hence, al-
though smoking, diabetes, CVD comorbidities, and biomarkers were
good predictors of either outcome, non-CVD comorbidities, de-
pression, and anxiety were mainly useful for predicting non-coronary
death. Importantly, the contribution of hypertension to model dis-
crimination was marginal and confined to coronary events. Since
blood pressure lowering trials among people with SCAD26
Figure 4 Evaluation of prediction performance upon incremental addition of different sets of predictors, using sociodemographics as the refer-
ence model. *Based on guideline definition of low (,1%), intermediate (1–3%), and high (.3%) annual risk. **Assuming that management is asso-
ciated with hazard ratio 0.8 and is cost-effective at high risk.
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demonstrate a reduction in both coronary and total mortality rates,
the prognostic effect of hypertension may be obscured by treatment.
Widely reported measures of model performance, such as the
C-index and the NRI, do not provide clinicians with readily interpret-
able evidence for making effective, and cost-effective decisions about
which patients should be further investigated.27 Following recom-
mendations,10 we therefore sought to estimate the potential
impact on patient outcomes of using the CALIBER prognostic
models for clinical decision making. Using these models to identify
patients at high risk (defined by guidelines as 3% annual mortality)
and offer a management strategy with a hazard ratio 0.8 (equivalent
to 20% absolute risk reduction) would save an additional 13–16
life years or 15–18 coronary-event-free life years over a 5-year
time horizon compared with a model including just age, sex, and
social deprivation. Hence, since the models are based on clinically
available data (i.e. there is no cost increment of collecting new
data), our analysis demonstrates that screening with the models is
likely to be cost-effective. However, economic evaluation would be
needed to establish their appropriateness in practice.
Stringent external validation is essential to ensure that a prognostic
model would be applicable to the rest of the population than the
patients in our cohort.21 However, a model can achieve impressive
performance (as high as in the development data) if applied to an ex-
ternal data set that originates from a similar source of data (e.g. valid-
ation of QRISK28 in data from a similar GP database system29). To
make our external validation rigorous, we therefore used a data set
with major differences from the development data set; the data
were collected differently (manually abstracted from case records),
the patients were at higher risk (received angiography due to chest
pain), and the study period was about a decade earlier with markedly
different background use of risk lowering medication. Hence, it was
reassuring that the models performed well in this external setting.
However, as with any prognostic model, there is an ongoing need
for further validation in external data sets and recalibration for differ-
ent populations and time periods.
We propose that the CALIBER prognostic models are implemented
in electronic health records in clinical practice. This should be done
alongside evaluation of the impact on decisions and, ultimately,
patient outcomes. The models may also be used to support adherence
to existing therapies, guide frequency of follow-up, plan trials of new
therapies, and serve as a reference on which to evaluate the extent to
which novel biomarkers might usefully further stratify risk assessment.
Limitations
A limitation in our study is that the electronic health record does not
capture all the information available to clinicians prior to imaging.
Thus, while clinicians assess symptom severity, this is not recorded
in standard fashion. However, we found that a proxy for symptom se-
verity, the use of long-acting nitrates, or repeat prescription for short
nitrates did add prognostic value. Although we had information from
the resting ECG on heart rate and the presence of atrial fibrillation,
resting ST segment, T wave, or other changes were seldom coded.
A further limitation was that for external evaluation, we ignored
(assumed absent) comorbidities not collected in the external data
set. However, the missing predictors had low impact on the perform-
ance of the models in the development data; thus, we do not expect
this to have affected the evaluation. Further, in order to represent all
relevant clinical parameters that are commonly considered in clinical
assessment, the models included a large number of variables.
However, these variables are routinely recorded in electronic
health records, so their collection is not associated with extra
costs. Also, the large size of the data set used to develop the
models reduces the likelihood of overfitting. Finally, only multiplica-
tive models were considered; models fitted in the additive scale are a
plausible alternative that was not explored.
Conclusions
In summary, we present validated prognostic models for estimating
risk of all-cause mortality and coronary outcomes based on clinical
parameters that are commonly available in all people with stable
coronary disease. These models can be implemented alongside
further medical investigations to support medical decision making.
However, as with any new prognostic model, further independent
evaluation is required in different settings including different elec-
tronic health record systems, health care organizations, and geo-
graphic locations to guide use in clinical practice. A risk calculator is
available online (www.caliberresearch.org/model).
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